Beijing HebaBiz Biotech was approved to start a China Phase III clinical study of Clevudine (L-FMAU), in patients with chronic hepatitis B virus (HBV). L-FMAU is a synthetic β-L nucleoside analogue that HebaBiz in-licensed from Yale University . The candidate binds to reverse transcriptase to inhibit HBV replication. HebaBiz says L-FMAU has a dual mechanism that provides antiviral activity while it causes a immune reaction, which it believes will sustain the suppression of the virus, giving L-FMAU the potential to be a functional cure. More details.... Share this with colleagues: // //